FDA Approves 10 Mcg Dose Of Vagifem® For The Treatment Of Atrophic Vaginitis Due To Menopause

Nordisk said that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem® (estradiol vaginal tablets) for the treatment of atrophic vaginitis due to menopause a condition experienced by up to 75 percent of postmenopausal women. This approval makes Vagifem® 10 mcg the lowest local estrogen therapy (LET) dose commercially available in the U.S…

source : www.medicalnewstoday.com

Related News:

• Mainstream media slants cancer articles toward unrealistically positive outcomes
• Florida Company Smart Nutra Inc. Makes Breakthough Advancement In The Treatment Of Lice
• New Surgery Without Incisions Shows Promise For Prostate Cancer Treatment
• Can We Trust What A Model Predicts?
• Biological Junk Reveals Treasure To People’s Choice Award Finalist, Australia
• iCo Therapeutics Inc. Receives Health Canada Clearance To Conduct Phase II DME Trial With iCo-007
• UB Researchers Propose A Novel Therapeutic Target For The Treatment Of Huntington’s Disease
• Do Certified Stroke Centers Deliver Speedy Treatment?
• Pool chemicals linked to disease
• Tarsa Therapeutics Advances Phase III ORACAL Trial Of Its Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis

Details :
Submited at Thursday, December 3rd, 2009 at 1:00 pm on Endocrinology by admin
Comment RSS 2.0 - leave a comment - trackback